ライフサイエンスコーパス: Fab fragment

1 anised and reformatted as a human IgG gamma1 Fab fragment.

2 competition with the C1 region-specific A32 Fab fragment.

3 CyRPA alone and in complex with an antibody Fab fragment.

4 ex with a specifically engineered monoclonal Fab fragment.

5 ell aggregation only as an IgG, but not as a Fab fragment.

6 ents linked site-specifically to a different Fab fragment.

7 ormation (-17 Da), were also detected in the Fab fragment.

8 solved structure of an antigen-bound 4-4-20 Fab fragment.

9 ch more effective at neutralization than its Fab fragment.

10 whole antibody but not with its F(ab)(2) or Fab fragments.

11 a quaternary complex with three neutralizing Fab fragments.

12 f intact antibodies relative to their Fc and Fab fragments.

13 rected to the B site neutralize the virus as Fab fragments.

14 IL-17A dimer sandwiched between two CAT-2200 Fab fragments.

15 iles comparable to that of the corresponding Fab fragments.

16 and the virion in complex with neutralizing Fab fragments.

17 cket formed between VH and VL domains of the Fab fragments.

18 in at 1.9 A, both in complex with monoclonal Fab fragments.

19 compared with that of 3-4 nm for the parent Fab fragments.

20 late complexes were expressed as recombinant Fab fragments.

21 ectra with the X-ray data for three antibody Fab fragments.

22 binary and ternary complexes between SEB and Fab fragments.

23 and by cryo-EM of complexes of virions with Fab fragments.

24 ) delivery of a sclerostin antibody-Fab (Scl-Fab) fragment.

25 ents based on both full-sized antibodies and Fab' fragments.

26 The most potent Fab fragment (2A4(GTP)) showed over 100-fold GTP-specifi

27 complex with strongly neutralizing antibody Fab fragments (8B10 and 5F10) were determined using cryo

28 lipid membranes and studied using monoclonal Fab fragments, a voltage-sensor toxin, and avidin bindin

29 An anti-factor D Fab fragment (AFD) was generated to inhibit the alternat

30 In contrast, microinjected Fab fragments against Listeria monocytogenes, an intrace

31 readily stained this antigen, microinjected Fab fragments against M. tuberculosis did not stain the

32 The nucleophilic sulfide of the Fab' fragments allows for specific orientations to be ac

33 NT4X and its Fab fragment also rescued working memory deficits in wil

34 However, monovalent 2D6 Fab fragments also inhibited V. cholerae motility, demon

35 enoted as Bs-F(ab)2] by linking two antibody Fab fragments, an anti-epidermal growth factor receptor

36 Modeling of a Fab fragment and crystal structures of the P dimer into

37 ally incorporated into an anti-Her2 antibody Fab fragment and full-length IgG in Escherichia coli and

38 In this study, the first GTP-specific Fab fragment and its application are described.

39 ure of a complex between the LT1009 antibody Fab fragment and S1P refined to 1.90 A resolution.

40 preincubated with an IL-6-blocking antibody Fab fragment and subjected to injury and TNFalpha treatm

41 sed conformation is most likely bound to the Fab fragment and that the antibody contact is localized

42 rowth factor) and two monovalent proteins (a Fab fragment and the transcription factor TBP) with low

43 ographic and competition binding analyses of Fab fragments and scFvs defined three spatially distinct

44 The beads were mixed with the corresponding Fab fragments and the sample.

45 erpreted using the crystal structures of the Fab fragments and the VLP structure.

46 examined the elbow angles for 365 different Fab fragments, and observe that Fabs with lambda light c

47 phrin type A receptor 2 (EphA2) bound to the Fab (fragment antigen binding) of an agonistic human ant

48 display library, we identified an anti-PCSK9 Fab (fragment antigen binding), 1G08, with subnanomolar

49 The crystal structure of DISC0280 Fab (fragment antigen binding), in complex with human IL

50 be attributed to cross-reactive, polyclonal Fab (fragment antigen-binding) specificities in serum as

51 ary was created with a natural repertoire of Fabs [fragment antigen binding (Fab)] from human naive B

52 A new Fab fragment antivenom (CroFab) for the treatment of cro

53 The increase in sensitivity obtained when Fab fragments are used instead of whole antibodies is ex

54 ing an oriented immobilization approach, the Fab' fragments are covalently attached to gold surface t

55 plex with rat monoclonal antibody YTS 105.18 Fab fragment at 2.88 A resolution.

56 However, the Fab' fragment-based biosensor displayed better regenerab

57 e antibodies/ethanolamine) and one optimized Fab' fragment-based surface (TUBTS/Fab' fragments) were

58 The autoantibody and its Fab fragment bind to the thyroid stimulating hormone (TS

59 24E9 Fab fragments bind DBLbeta3_D4 with nanomolar affinity a

60 The Fab fragment binding the J1 epitope was crystallized, an

61 Finally, an A32 Fab fragment blocked the majority of ADCC-mediating Ab a

62 T cell receptor (TCR)-like antibody 25-D1.16 Fab fragment bound to a complex of SIINFEKL peptide from

63 tion cryo-electron microscopy structure of a Fab fragment bound to CHIKV E2 B domain provided an expl

64 ystal structures: the murine antibody 125-2H Fab fragment bound to human IL-18, at 1.5 A resolution;

65 ptamine 2B (5-HT2B) receptor and an antibody Fab fragment bound to the extracellular side of the rece

66 Reconstructions of complexes with Fab fragments bound to N or C termini of PDE6gamma revea

67 yed the accessibility of the bacteria to the Fab fragments by both immunofluorescence microscopy and

68 tralized by the addition of the anti-beta(3) Fab fragment, c7E3, or specific ANDV- or HTNV-neutralizi

69 Thus, Fab fragments can adopt a conformation that is compatibl

70 (13)C NMR spectra of protease-cleaved Fc and Fab fragments can provide accurate reporters on the doma

71 ng complexes composed of three stably linked Fab fragments capable of selective delivery of radiotrac

72 In contrast, monovalent invasion-inhibitory Fab fragments caused accumulation of 66- and 52-kDa form

73 r chimeric or human in sequence, a PEGylated Fab' fragment (certolizumab), and an IgG1-TNFR2 fusion p

74 In the case of the AD-2S1 peptide, the KE5 Fab fragment complex identified nine germline-encoded co

75 urine monoclonal IgG2b(kappa) antibody NC6.8 Fab fragment complexed with high-potency sweetener compo

76 CryoEM maps of neutralizing Fab fragments complexed with VLPs have been interpreted

77 the scFv SAM PZ is superior to Fab fragment, Fab fragment containing a free sulfhydryl group (i.e., F

78 V(H) domain between Cys22 and Cys96, and the Fab fragment, containing the unpaired cysteine residues,

79 Neutralizing Fab fragments cover the outer surface of each copy of th

80 ithin one trimeric spike, whereas the 3B4C-4 Fab fragment cross-links E2 proteins from neighboring sp

81 The F5 Fab fragment cross-links E2 proteins within one trimeric

82 Both of these antibody Fab fragments cross-link the surface E2 glycoproteins an

83 nal ovine anti-TNF fragment antigen binding (Fab) fragments (CytoFab) on plasma TNF-alpha, interleuki

84 2+ and the bivalent (Fab)2 or the monovalent Fab fragments derived from limited proteolysis of the co

85 TGN1412 was investigated using F(ab')(2) and Fab fragments derived from TGN1412 recovered from the tr

86 Monoclonal antibody fragments included Fab' fragments derived from C225, which binds both EGFR

87 highly potent anti-human interleukin (IL)-13 Fab fragment designed for administration by inhalation.

88 ellular domain (ECD) complexed to the ABT007 Fab fragment, determined at 0.32 nm, identifies a bindin

89 ate exocytosis, because the W6/32 monovalent Fab fragment did not activate VWF release, but the bival

90 In contrast, the monovalent 2F5 Fab fragment did not exhibit any appreciable change in n

91 ar measurements in the presence of anti-CS20 Fab fragments did not show any effect, indicating that b

92 The Fab fragment differed from the intact antibody only in t

93 in-expressing M. tuberculosis, microinjected Fab fragments directed against a major surface antigen o

94 Certain antibody Fab fragments directed against the C terminus of outer s

95 Bound Fab' fragments display higher surface densities, yieldin

96 are required for enhanced binding, since 3G4 Fab' fragments do not bind EC with exposed PS.

97 Structurally, the E16 antibody Fab fragment engages 16 residues positioned on four loop

98 esult from their bivalent nature: monovalent Fab fragments exhibited a similar affinity for the fibri

99 The Fab fragment exhibits novel complementarity determining

100 It combines high-throughput Fab fragment expression and purification with surface pl

101 plex with two strongly neutralizing antibody Fab fragments (F5 and 3B4C-4) have been determined using

102 One peptide is conjugated to the Fab' fragment (Fab'-CCE), the other is conjugated in mul

103 onucleotide (MORF1) attached to an anti-CD20 Fab' fragment (Fab'-MORF1); (2) multiple copies of compl

104 ata show that the scFv SAM PZ is superior to Fab fragment, Fab fragment containing a free sulfhydryl

105 as to use (64)Cu-labeled anti-CD105 antibody Fab fragment for noninvasive assessment of angiogenesis

106 1 cleavage results in formation of identical Fab fragments for each of the molecular forms, thereby a

107 ful radiotracers (e.g., (99m)Tc, (188)Re) to Fab fragments for potential noninvasive imaging and ther

108 are functionalized with anti MC-LR antibody Fab' fragments for the selective capture of MC-LR from a

109 ncept using bovine serum albumin (BSA) and a Fab fragment from a BSA-binding polyclonal antibody.

110 mmune responses of rat lymph node cells by a Fab fragment from a CD5 mAb shown to block homophilic in

111 ain 1 was inhibited by mutation or by IgG or Fab fragment from a CD5 mAb.

112 have determined the crystal structure of the Fab fragment from F105, a broadly reactive human antibod

113 revious study, repertoire cloning to recover Fab fragments from bone marrow mRNA of chimpanzees infec

114 Fab fragments from MAb 166 prevent sepsis and death.

115 interested in the codon usage of an antibody Fab fragment gene exhibiting extreme toxicity in the E.

116 -PcpA, and -Ply antibodies were purified and Fab fragments generated.

117 H-induced phosphorylation, whereas monomeric Fab fragments had no effect.

118 The nature of the Fab' fragment had an influence on its residence time as

119 Antibody Fab fragments have been exploited with significant succe

120 Using this technique, monoclonal scFv and Fab fragments have been produced that bind to the 51-kDa

121 as well as their complexes with each of two Fab fragments (HuM-P and HuM-R1), which recognize N- and

122 , we determined the crystal structure of 5G6 Fab fragment in complex with its epitope peptide KL10 (G

123 ture of the linear-linkage-specific antibody Fab fragment in complex with linear diubiquitin provides

124 l structure of an anti-LPA antibody (LT3015) Fab fragment in its antigen-free form to 2.15 A resoluti

125 sical properties of a selection of humanised Fab fragments in a number of assays allowed us to select

126 ic constants (kon and koff) for 96 different Fab fragments in a single experiment.

127 c level, we determined crystal structures of Fab fragments in complex with Abeta.

128 ere are two crystallographically independent Fab fragments in the asymmetric unit.

129 The extracellular surface location of the Fab fragments in the map is consistent with the membrane

130 d domain interactions for IgG antibodies and Fab fragments in the structural database.

131 Here, the crystal structure of the B4e8 Fab' fragment in complex with a 24-mer V3 peptide (RP142

132 fect on the residence time of an anti-IL-17A Fab' fragment in the lungs of mice.

133 given to show the versatility of immobilized Fab' fragments in different applications and future dire

134 dence time of the anti-IL-17A and anti-IL-13 Fab' fragments in the lungs but PEGylation was able to p

135 ecause nuclear microinjection of anti-pigpen Fab fragments inhibited endothelial cell division.

136 lly, we engineer mouse hybridomas to secrete Fab' fragments instead of the whole Ig.

137 lographically determined structures of these Fab fragments into the cryo-electron density maps, we sh

138 Sequence analysis of 55 6B-specific antibody Fab fragments isolated from six vaccinated donors reveal

139 ing proteins, each consisting of 2 identical Fab fragments linked site-specifically to a different Fa

140 eir variable segments, suggesting that bound Fab fragments may neutralize the inhibitory effect of ne

141 Neither H-specific Fab fragments nor H-specific IgM could enhance MV entry

142 The structures of Fab fragments not determined crystallographically were p

143 dothelial cell activation, whereas monomeric Fab fragments not only did not cause activation, but blo

144 e Fab fragment of MA28-7 shows that only one Fab fragment occupies each 5-fold vertex.

145 d alphaVbeta3 ectodomain in complex with the Fab fragment of 17E6.

146 burnetii infection, we examined whether the Fab fragment of 1E4 (Fab1E4), a recombinant murine singl

147 cture of the HCMV gB ectodomain bound to the Fab fragment of 1G2, a neutralizing human monoclonal ant

148 e combined immunodeficiency treated with the Fab fragment of a blocking antibody recognizing a signal

149 and other countries: abciximab (ReoPro; the Fab fragment of a chimeric human-mouse antibody), eptifi

150 mbinant PAK pilin peptide in complex with an Fab fragment of a cross-reactive monoclonal antibody, PA

151 /2013, French Polynesia) in complex with the Fab fragment of a highly therapeutic and neutralizing hu

152 ies of the GI.1 P domain in complex with the Fab fragment of a human IgA monoclonal antibody (IgA 5I2

153 f a soluble form of CD28 in complex with the Fab fragment of a mitogenic antibody.

154 ether bond modification was confirmed in the Fab fragment of a monoclonal antibody by LC-MS and nonre

155 The Fab fragment of a monoclonal IgM cleaved gp120, suggesti

156 An Fab fragment of a monospecific antibody, which binds to

157 .4 angstrom resolution of VP7 bound with the Fab fragment of a neutralizing monoclonal antibody.

158 terferon alpha-2A (IFN-alpha2A) bound to the Fab fragment of a therapeutic monoclonal antibody (sifal

159 etermined the X-ray crystal structure of the Fab fragment of Ab52 and derived an antibody-antigen com

160 e, we describe the crystal structures of the Fab fragment of AL-57 in complex with IA, as well as in

161 ere we describe the crystal structure of the Fab fragment of an antagonistic monoclonal antibody KTN3

162 l means of antigen recognition, in which the Fab fragment of an antibody acts as an adaptor, linking

163 ex formed by LTalpha1beta2, LTbetaR, and the fab fragment of an antibody that blocks LTbetaR activati

164 linked to the C terminus of the heavy chain Fab fragment of an HIV-1 envelope antibody.

165 our results to the crystal structure of the Fab fragment of anti-Le(x) mAb 291-2G3-A complexed with

166 The co-crystal structure of Shh bound to the Fab fragment of ch5E1 reveals that 5E1 binds at the pseu

167 ructure of the Michaelis complex between the Fab fragment of ferrochelatase antibody 7G12 and its sub

168 I domain of the alpha1beta1 integrin and the Fab fragment of humanized AQC2 antibody.

169 The Fab fragment of ligand-induced binding site-6 (LIBS6) an

170 th HepG2 cells in culture indicated that the Fab fragment of M27 does not block binding and uptake of

171 structure of a complex between EV71 and the Fab fragment of MA28-7 shows that only one Fab fragment

172 We determined the crystal structures of the Fab fragment of mAb 107 complexed to the low- and high-a

173 Binding of the Fab fragment of mAb 107 to CD11bA did not trigger the ac

174 Upon binding to Der p 1, the Fab fragment of mAb 10B9 was found to form a very rare a

175 rystal structure of the epitope bound to the Fab fragment of MAb 2F5 has shown that the 2F5 peptide a

176 Furthermore, as the Fab fragment of mAb32 had no effect on IN activity, inhi

177 ure of the nAChR alpha1 subunit bound by the Fab fragment of mAb35, a reference monoclonal antibody t

178 tal structure of the ECD in complex with the Fab fragment of one antibody, mAb1, reveals that this an

179 Here, we present the structure of the Fab fragment of such an antibody.

180 The structure of a complex between the Fab fragment of the antibody (SYA/J6) specific for the c

181 e reported for mesoporphyrin IX bound to the Fab fragment of the ferrochelatase antibody 7G12.

182 The crystal structures of the Fab fragment of the germ-line precursor antibody to 7G12

183 PNU-214936 is a murine Fab fragment of the monoclonal antibody 5T4 fused to a m

184 mice (MVMi) in complex with the neutralizing Fab fragment of the mouse monoclonal antibody (MAb) B7 w

185 Fab fragment of the recombinant human IgG was analyzed d

186 The structure of WNV complexed with the Fab fragment of the strongly neutralizing mAb E16 was de

187 s of the 'highly ordered' interaction of the Fab fragment of this antibody (Fab-2H10) with VEGF-B.

188 e crystal structure of C3b in complex with a Fab fragment of this antibody (S77) illustrates the stru

189 Fab fragment of TRC105, a mAb that specifically binds to

190 Here, we report the crystal structure of the Fab fragment of Z13e1, an affinity-enhanced variant of m

191 The crystal structures of four related Fab fragments of a family of catalytic antibodies displa

192 Fab fragments of a monoclonal IgM Ab expressed catalytic

193 modeling to visualize capsids decorated with Fab fragments of a receptor immunoglobulin, and surface

194 Intact and Fab fragments of alpha Arp2 inhibited TRAP-stimulated ac

195 Addition of Fab fragments of an FcgammaRIIa-specific monoclonal anti

196 ), followed by dual enzymatic labeling using Fab fragments of anti-Dig and anti-FITC conjugated to pe

197 , although monovalent HEL, unlike monovalent Fab fragments of anti-Ig, readily triggered the BCR.

198 In contrast, Fab fragments of antibody 5F10 bind the tip of the E2 B

199 the cryo-electron density maps, we show that Fab fragments of antibody 8B10 extend radially from the

200 radii; (ii) determination of the binding of Fab fragments of anticapsular antibodies as a measure of

201 rminal half of the TcdB CROP domain bound to Fab fragments of bezlotoxumab.

202 termined the structure of WNV complexed with Fab fragments of CR4354 using cryoelectron microscopy.

203 resolution of 2.5 A of a complex between the Fab fragments of E1 and HM14c10 and provide the first de

204 resolution of 2.5 A of a complex between the Fab fragments of E1 and HM14c10 provides the first detai

205 f 8A11 with saturating concentrations of the Fab fragments of goat antibodies directed against the Fc

206 oreover, Lmsp1 binds to both purified Fc and Fab fragments of IgG from both humans and rabbits.

207 over intact IgG, as observed in the case of Fab fragments of MAb 4G2dc1.

208 Structural analyses of Fab fragments of mAbs 023.102 and pn132p2C05 in complex

209 al structures of Der p 1 in complex with the Fab fragments of mAbs 5H8 or 10B9.

210 Blocking of BDCA-2 and DCIR with Fab fragments of monoclonal antibodies preserves the cap

211 Here we used the Fab fragments of new monoclonal anti-FcRH1 antibodies an

212 Purified Fab fragments of NMO-IgG showed similar patterns of AQP4

213 Fab fragments of PG102, while retaining CD40 binding, di

214 ide (LPS), polyclonal anti-R. conorii serum, Fab fragments of polyclonal antiserum, or no antibodies

215 Moreover, Fab fragments of polyclonal IgG that fail to cross-link

216 Co-crystal structures with Fab fragments of protective antibodies will further deli

217 rystallized Factor IX-(1-47) in complex with Fab fragments of the 10C12 antibody.

218 bited by preincubation of the platelets with Fab fragments of the FcgammaRIIa-specific mAb IV.3 or wi

219 Additionally, the Fab fragments of the mAbs were able to enter neurons, bu

220 Here we have used Fab fragments of the neutralizing antibody DV2-E104 to s

221 This was accomplished by binding Fab fragments of the neutralizing antibody DV2-E104 to t

222 dies, monoclonal antibodies to OmpA or OmpB, Fab fragments of the polyclonal antibodies, or normal se

223 structures of the allergens in complex with Fab fragments of three murine mAbs that interfere with I

224 We have investigated complexes of the Fab fragments of two antibodies that have parasite inhib

225 1 primary isolate spike, we crystallized the Fab fragments of two mAbs, GE136 and GE148.

226 In this study, we focused on the Fab fragments of two monoclonal antibodies, E1 and 3120.

227 D4-stabilized gp120 cores complexed with the Fab fragments of two nonneutralizing, A32-like monoclona

228 he German cockroach allergen Bla g 2 and the Fab' fragment of a monoclonal antibody 7C11 was solved a

229 The crystal structures of the Fab' fragment of H5M9 in complexes with H5 HAs of A/Viet

230 and CCK, forming antiparallel heterodimers; Fab' fragment of the 1F5 anti-CD20 antibody; and N-(2-hy

231 articles are reacted with the free thiols of Fab' fragments of an anti-alkaline phosphatase (ALP) ant

232 unoliposomes were constructed modularly with Fab' fragments of cetuximab (IMC-C225), covalently linke

233 However, treatment of Y7A KI mice with Fab' fragments of the function-blocking anti-CLEC-2 anti

234 n antibody; 5C4, a fragment antigen-binding (Fab fragment) of monoclonal rat immunoglobulin G; and m-

235 ified high affinity or bivalent single chain Fab fragments, offering higher specificity and possibili

236 ientation of the self-assembled monolayer of Fab' fragments on the gold-coated particles compared to

237 one and pendant MORF2, and comparison of two Fab' fragments, one from 1F5 antibody (Fab'1F5), the oth

238 required receptor dimerization as monovalent Fab fragments only eliminated receptor levels or reduced

239 tremendous progress in the immobilization of Fab' fragments onto gold, Si-based, polysaccharide-based

240 CDP860 is an engineered Fab' fragment-polyethylene glycol conjugate, which binds

241 d by proteolytic cleavage of immunoglobulin, Fab fragments possess great promise as blocking reagents

242 A monovalent Fab fragment prepared from the native protein and a biva

243 ng and internalization of surface NMDARs, as Fab fragments prepared from patients' antibodies did not

244 Binding of the DV2-E104 Fab fragments prevents domain III from rotating by about

245 e demonstrate that the antibody NT4X and its Fab fragment reacting with both the free N-terminus of A

246 rrespond to exposed epitopes in vivo, as the Fab fragments recognize native MOG in situ in marmoset b

247 Recombinant Fab fragments recognizing different conformations of thi

248 anti-beta(3) antibodies such as c7E3 or its Fab fragment ReoPro prevents hantavirus entry.

249 atic, exposure of V. cholerae to 2D6 IgA (or Fab fragments) resulted in a 5-fold increase in surface-

250 chia coli ClC channels bound to a monoclonal Fab fragment reveal three Cl- binding sites within the 1

251 X-ray crystallography of an anti-E-gp120 Fab fragment revealed two neighboring cavities, the typi

252 on with small interfering RNAs and anti-CD63 Fab fragments revealed that CD63 itself was not required

253 n issue in the development of the biosensor, Fab' fragments should be chosen as they are relatively c

254 We developed a ligand-mimetic antibody Fab fragment specific for Drosophila alphaPS2betaPS inte

255 analysis were used to isolate human antibody Fab fragments specific for the capsular polysaccharide o

256 The Fab fragments stabilized the position of the B domain re

257 This antibody or its Fab fragments substantially decreased the level of bindi

258 were also disrupted by a monovalent A45-B/B3 Fab fragment, suggesting that the binding of the antibod

259 ix E monomers within one raft by four CR4354 Fab fragments suggests that the antibody neutralizes WNV

260 An engineered human antibody Fab fragment that binds to the P. aeruginosa PcrV protei

261 acting the maleimide-derivatized trastuzumab Fab fragments that bind HER2 with a thiolated form of th

262 Certolizumab pegol is a pegylated humanized Fab' fragment that binds tumor necrosis factor alpha.

263 a recombinant, PEGylated, engineered, human Fab' fragment that specifically binds to a Pseudomonas a

264 smon resonance revealed a dense monolayer of Fab' fragments that are on average 90% active when speci

265 because both whole IgG anti-CD73 AD2 mAb and Fab' fragments thereof exhibited this effect.

266 r with the neutralizing capacity of the 3/11 Fab fragment, this indicates an unexpected structural fl

267 and EGFR on BC cells by linking trastuzumab Fab fragments through a polyethylene glycol (PEG24) spac

268 The similar binding properties of 5G6 Fab fragment to GPIbalpha on human platelets as those to

269 The affinities of intact rituximab and its Fab fragment to the isolated and purified CD20 are simil

270 of a Fc-specific anti-human immunoglobulin G Fab fragment to the virus-antibody mixture prior to infe

271 In an in vitro system, tethering of Fab fragments to DNA ends inhibits MRX-mediated DNA end

272 Using blocking Fab fragments to each Plg-R, H2B supported approximately

273 nding of FITC-labeled 23G3 intact Ab and its Fab' fragment to cell-surface IgE.

274 echnetium-99m-labeled deimmunized antifibrin Fab' fragments to diagnose thromboemboli using single ph

275 o immobilize whole anti-PTHrP antibodies and Fab' fragments to surfaces as biorecognition elements.

276 of intact mAb and fragment antigen-binding (Fab) fragments to platelets showed that affinity is incr

277 Passive transfer of antibodies, but not Fab fragments, to E. muris protected C3H/SCID mice again

278 We used a ligand-mimetic Fab fragment, TWOW-1, to assess talin's role in regulati

279 to labeling of human serum albumin (HSA) and Fab fragments under aqueous conditions.

280 We selected Fab fragments using the phage display technology.

281 ty of an HA-specific MAb (VN and YR) and its Fab fragment (VN) by intranasal (i.n.) administration to

282 holo-PDE6 in complex with the ROS-1 antibody Fab fragment was determined by cryo-electron microscopy.

283 The crystal structure of ch8H9 Fab fragment was solved to 2.5-A resolution and used as

284 IgG, and the neutralization efficacy of E33 Fab fragments was not affected by changes in the virion

285 L with neutralizing monoclonal antibodies or Fab' fragments was also consistent with a two-step react

286 eding bacterial motility, whereas monovalent Fab fragments were 5- to 10-fold less effective.

287 Fab fragments were attached to 'voltage sensor paddles'

288 Crystal structures of the corresponding Fab fragments were determined in complex with hypusine-

289 Six Fab fragments were found against 2'/3'-GTP-biotin and 8-

290 the recipients of anti-LPS antibodies or the Fab fragments were not protected.

291 as not required for protection because C3.78 Fab' fragments were as effective as whole antibody molec

292 optimized Fab' fragment-based surface (TUBTS/Fab' fragments) were tested as biosensors.

293 (single chain variable and antigen-binding (Fab) fragments), which recognize the structurally divers

294 G2 and the crystal structure of the antibody Fab fragment, which was solved at 2.4 A resolution.

295 We characterize these monoclonal antibody Fab fragments, which are known to abrogate VEEV infectiv

296 al structure of the complex between C5 and a Fab fragment with the same sequence as eculizumab at a r

297 and pharmacodynamics (PD) of 2F5 IgG and 2F5 Fab fragments with respect to protection against vaginal

298 f delivery of the anti-IL-17A and anti-IL-13 Fab' fragments within the lungs had a major impact on th

299 However, a novel CD4i-specific Fab fragment, X5, has recently been found to neutralize

300 The immobilization of only Fab' fragments yields benefits over the more traditional